Clinical trialsCompany release

CAMP4 secures UK and EU clearances for SYNGAP1 trial of CMP-002

🇺🇸 Camp4 Therapeutics Corp (CAMP) · Thu 05 Nov 2026

The MHRA and several EU regulators and ethics committees have authorised sites in the Phase 1/2 ASCEND study, with first dosing still expected by the end of 2026.

CAMP4 Therapeutics has obtained further regulatory authorisations for its Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder, the company said as it reported third-quarter results on 5 November 2026.

The UK's Medicines and Healthcare products Regulatory Agency authorised sites in September. In October, multiple EU regulators and ethics committees followed. These clearances add to approvals already received in July in Australia and Argentina.

CAMP4 said it continues to expect to dose its first patient by the end of 2026.

On the financial side, the company reported cash of $124.5 million, a figure that reflects the closing of a $50.1 million private placement. It also reported a net loss of $29.0 million for the quarter. The headline of the company's announcement points to a cash runway extending to the end of 2028.

What it means for your team

  • Sponsors running multinational early-phase studies can see UK and EU site approvals arrive on separate timelines, so country-by-country planning remains necessary.
  • With authorisations now spanning the UK, EU, Australia and Argentina, ASCEND is positioned for multi-region start-up, which will matter for site activation and safety reporting set-up.
  • Teams tracking rare neurodevelopmental disease programmes should note that first-patient dosing, not authorisation, is the next milestone the company has flagged for year-end 2026.

Company's press release (SEC filing): Camp4 Therapeutics Corp ↗

Article written by VigiEye from the official source (Camp4 Therapeutics Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →